Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of PF-06651600 in healthy subjects
NCT02309827Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ritlecitinib tosilate in inflammatory bowel disease (IBD) (9 cohorts), sponsored by Pfizer. Primary endpoints: 24 hour creatinine clearance at Day 14, Change from baseline in urine volume at Day 14 and 2 more. Started Dec 2014; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02309827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309827.